#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Biotinidase deficiency IgA nephropathy Dermatitis Cytokine release syndrome Prolymphocytic leukaemia Myxoid liposarcoma Haemolytic uraemic syndrome Non-Hodgkin's lymphoma Hyperinsulinaemic hypoglycaemia Carcinoid syndrome Osteosarcoma Spinal muscular atrophy Lennox-Gastaut syndrome Lymphatic malformation Mixed-type liposarcoma More trials…

    Learn about Rare Diseases

    Behcet’s syndrome – Treatment Angiosarcoma non-metastatic – Trials in Disease Synovial sarcoma – Trials in Disease Rett syndrome – Treatment Inclusion body myositis – Trials in Disease Marfan’s syndrome – Diagnostics Haemophilia B without inhibitors – Trials in Disease Hypereosinophilic syndrome – Trials in Disease Splenic marginal zone lymphoma – Basic Information Angiosarcoma recurrent – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Abc-31-116 Kbp-336 Tulisokibart Tenofovir Disoproxil Rizolipase Deucravacitinib Vemircopan Meropenem Trihydrate Oxybuprocaine Hydrochloride VAMIFEPORT TRIHYDROCHLORIDE Linperlisib CEFTAROLINE FOSAMIL Tusamitamab Ravtansine Emicizumab Zanubrutinib PALAZESTRANT Tafasitamab Fluocinolone Acetonide Diphenhydramine Hydrochloride Emrusolmin More therapies…

    Learn about Your Condition

    Vertigo Liver transplant Neurodegenerative disorder Hairy cell leukaemia recurrent Conjunctivitis allergic Lichenoid keratosis Mucopolysaccharidosis I Emphysema Hepatocellular carcinoma Medulloblastoma Renal disorder Apathy Transplant rejection Embolic stroke Peripheral artery thrombosis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Institut Regional Du Cancer De Montpellier

Institut Regional Du Cancer De Montpellier

208 Avenue Des Apothicaires, Montpellier, 34298, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    • Breast cancer
    Investigated Drugs:
    • Eribulin Mesylate
    • Capecitabine
    • Gemcitabine Hydrochloride
    Austria Belgium France Germany Greece Italy +2

  • Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Busulfan
    • Dinutuximab Beta
    • Melphalan
    Austria Belgium Czechia Denmark Finland France +13

  • Study on the Effectiveness of Doxorubicin, Ifosfamide, and Dacarbazine in High-Risk Patients with Resectable Soft-Tissue Sarcoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Soft tissue sarcoma
    Investigated Drugs:
    • Dacarbazine
    • Doxorubicin Hydrochloride
    • Ifosfamide
    France

  • Study on the Effectiveness of GP2 and Sargramostim for HER2 Positive Breast Cancer Patients with Residual Disease or High-Risk After Standard Therapy

    Recruiting

    3 1
    Investigated Diseases:
    • Breast cancer
    • HER2 positive breast cancer
    Investigated Drugs:
    • L-Isoleucyl-L-Isoleucyl-L-Seryl-L-Alanyl-L-Valyl-L-Valyl-Glycyl-L-Isoleucyl-L-Leucine
    • Sargramostim
    Austria Belgium France Germany Ireland Italy +4

  • Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Caffeine
    • Acetylsalicylic Acid
    Czechia Denmark France Germany Italy The Netherlands +3

  • Study on RYZ101 for Patients with Advanced Gastroenteropancreatic Neuroendocrine Tumors After Previous Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Actinium (Ac 225) Oxodotreotide
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    Belgium France The Netherlands Spain

  • Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Investigated Drugs:
    • Darolutamide
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Renal cell carcinoma
    Investigated Drugs:
    • Axitinib
    • Cabozantinib
    • Ipilimumab
    Austria Belgium Czechia Denmark Finland France +5

  • Study on Retreatment with Lutetium (177Lu) Oxodotreotide for Patients with Intestinal Neuroendocrine Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour
    Investigated Drugs:
    • L-Arginine Hydrochloride
    • L-Lysine Hydrochloride
    • Lutetium (177Lu) Oxodotreotide
    France

  • Study on Managing Locally-Advanced Rectal Cancer with Oxaliplatin, Fluorouracil, and Irinotecan Hydrochloride for Patients Responding Well to Initial Chemotherapy

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Rectal cancer
    Investigated Drugs:
    • Irinotecan Hydrochloride
    • Calcium Folinate
    • Capecitabine
    France
Previous Page
1 … 5 6 7 8 9 … 25
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!